

Label-free Method for Classification of T cell Activation

Alex J. Walsh^{1,*}, Katie Mueller^{2,3}, Isabel Jones¹, Christine M. Walsh^{1,4}, Nicole Piscopo^{2,3},
Natalie N. Niemi^{1,5}, David J. Pagliarini^{1,5}, Krishanu Saha^{2,3} and Melissa C. Skala^{1,3,*}

¹Morgridge Institute for Research, Madison, Wisconsin

²Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, Wisconsin

³Department of Biomedical Engineering, University of Wisconsin-Madison, Madison,
Wisconsin

⁴Department of Sociology, State University of New York, Albany, New York

⁵Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin

*Corresponding Authors

Abstract

T cells have a range of cytotoxic and immune-modulating functions, depending on activation state and subtype. However, current methods to assess T cell function use exogenous labels that often require cell permeabilization, which is limiting for time-course studies of T cell activation and non-destructive quality control of immunotherapies. Label-free optical imaging is an attractive solution. Here, we use autofluorescence imaging of NAD(P)H and FAD, co-enzymes of metabolism, to quantify optical imaging endpoints in quiescent and activated T cells. Machine learning classification models were developed for label-free, non-destructive determination of T cell activation state. T cells were isolated from the peripheral blood of human donors, and a subset were activated with a tetrameric antibody against CD2/CD3/CD28 surface ligands. NAD(P)H and FAD autofluorescence intensity and lifetime of the T cells were imaged using a multiphoton fluorescence lifetime microscope. Significant differences in autofluorescence imaging endpoints were observed between quiescent and activated T cells. Feature selection methods revealed that the contribution of the short NAD(P)H lifetime (α_1) is the most important feature for classification of activation state, across multiple donors and T cell subsets. Logistic regression models achieved 97-99% accuracy for classification of T cell activation from the autofluorescence imaging endpoints. Additionally, autofluorescence imaging revealed NAD(P)H and FAD autofluorescence differences between CD3⁺CD8⁺ and CD3⁺CD4⁺ T cells, and random forest models of the autofluorescence imaging endpoints achieved 97+% accuracy for four-group classification of quiescent and activated CD3⁺CD8⁺ and CD3⁺CD4⁺ T

29 cells. Altogether these results indicate that autofluorescence imaging of NAD(P)H and FAD is a powerful
30 method for label-free, non-destructive determination of T cell activation and subtype, which could have
31 important applications for the treatment of cancer, autoimmune, infectious, and other diseases.

32 1 Introduction

33 T cells are an important component of the adaptive immune response and have diverse cytotoxic and immune-
34 modulating, or “helper” activities, upon activation. The two main T cell subtypes are CD3⁺CD8⁺ T cells
35 that engage in cell-mediated cytotoxicity and release toxic cytokines, including interferon gamma (IFN- γ)
36 and tumor necrosis factor alpha (TNF- α), and CD3⁺CD4⁺ T cells that can be further divided into additional
37 subtypes with differing pro- and anti- inflammatory functions due to chemokine and cytokine production[1, 2].
38 T cells are a promising target for immunotherapies because of these diverse functions. Immunotherapies that
39 directly increase T cell cytotoxic activity, such as immune checkpoint blockade therapies and adoptive cell
40 transfer therapies, are currently used clinically for cancer treatment and are in development for additional
41 diseases including HIV[3, 4]. Immunotherapies that enhance regulatory T cell (T_{REG}) behaviors are in
42 development to treat transplant rejection and autoimmune diseases, including diabetes and Crohn’s disease
43 [5–7]. Due to the variable behaviors of T cell subsets, full evaluation of immunotherapy efficacy requires
44 profiling of T cell subtypes and activation states to assess the impact of different T cell compartments on
45 the patient, select for appropriate therapeutic cell populations, and evaluate the degree of response upon
46 stimulation.

47 New tools that are non-destructive and label-free are needed to fully characterize T cells for assessment of
48 immunotherapies. Currently, T cell subtype and function is determined from expression of surface proteins
49 (e.g. CD3, CD4, CD8, CD45RA, etc.) and cytokine production (e.g. IFN- γ , TGF- β , IL-2, IL-4, IL-17, etc.)
50 by antibody-based methods such as flow cytometry, immunohistochemistry, or immunofluorescence, or by
51 transgenic fluorophore expression. However, all of these methods require exogenous contrast agents, and flow
52 cytometry and immunohistochemistry require tissue dissociation and fixation, respectively. A non-destructive
53 and label-free method of determining T cell activity would enable direct observation of T cell behavior and
54 immunotherapy effects *in vivo* in preclinical models of cancer. Additionally, such a tool could be amenable
55 for single-cell quality control of adoptive T cell therapies, where T cells, expanded *in vitro*, are injected into
56 the patient. Autofluorescence imaging is an attractive method to probe immune cell behaviors because it is
57 non-destructive, relies on endogenous contrast, and provides high spatial and temporal resolution.

58 Fluorescence imaging of the endogenous metabolic co-enzymes NAD(P)H and FAD provides quantitative
59 endpoints of cellular metabolism [8–10]. (NADH and NADPH fluorescence are indistinguishable; therefore,

60 NAD(P)H is used to represent the combined fluorescence signal[11].) The optical redox ratio is the fluo-
61 rescence intensity of NAD(P)H divided by the sum of the fluorescence intensities of NAD(P)H and FAD,
62 and provides an optical measurement of the redox state of the cell [8, 12]. The fluorescence lifetime, the
63 time the fluorophore is in the excited state before returning to ground state, provides information on the
64 protein binding of NAD(P)H and FAD [9, 13]. NAD(P)H and FAD can both exist in two conformations: a
65 quenched and unquenched form, with a short and long lifetime, respectively. NAD(P)H has a short lifetime
66 in the free state and a long lifetime in its protein-bound state [9]. Conversely, FAD has a short lifetime
67 when bound to an enzyme and a long lifetime when free [13]. Fluorescence lifetime imaging (FLIM) allows
68 quantification of the short (τ_1) and long (τ_2) lifetime values, the fraction of free and protein-bound co-enzyme
69 (α_1 and α_2 , respectively, for NAD(P)H, and α_2 and α_1 , respectively, for FAD), and the mean lifetime (the
70 weighted average of the short and long lifetimes, $\tau_m = \alpha_1 * \tau_1 + \alpha_2 * \tau_2$). The fluorescence intensity and
71 lifetime of NAD(P)H and FAD are sensitive to metabolic differences between neoplasias and malignant tis-
72 sues, anti-cancer drug effects in cancer cells, and differentiating stem cells [14–19]. Autofluorescence imaging
73 has been used previously to identify macrophages *in vivo* and detect metabolic changes due to macrophage
74 polarization [20–22]. Altogether, fluorescence lifetime imaging of NAD(P)H and FAD provide quantitative
75 and functional endpoints of cellular metabolism.

76 T cells undergo metabolic reprogramming when activated by an antigen. Upon activation, T cells have
77 increased metabolic demands to support cell growth, proliferation, and differentiation [23]. CD28 stimulation
78 induces glucose uptake and glycolysis in T cells through upregulation of GLUT1, phosphatidylinositol 3'-
79 kinase (PI3K), and Akt. This metabolic state of increased aerobic glycolysis is required for T cells to maintain
80 effector function [23–25]. Therefore, this study tests the hypothesis that fluorescence lifetime imaging of
81 NAD(P)H and FAD provides a label-free, non-destructive method with quantitative endpoints to identify
82 activated T cells. To test this hypothesis, we isolated T cells from the blood of healthy donors, activated
83 the cells in an antigen-independent manner with a tetrameric antibody (anti-CD2/CD3/CD28) and imaged
84 the NAD(P)H and FAD fluorescence intensity and lifetime of quiescent and activated T cells. This is the
85 first study to (1) demonstrate autofluorescence lifetime differences between quiescent and activated T cells
86 and (2) accurately classify T cell activation state from machine learning models using quantitative endpoints
87 from autofluorescence lifetime images.

88 2 Results

89 2.1 Autofluorescence imaging reveals metabolic differences with activation in 90 T cells.

91 T cell isolations for CD3⁺ (pan-T cell marker) and CD3⁺CD8⁺ cells were used to study all T cells, as might
92 be utilized in adoptive cell transfer therapies, and the cytotoxic CD3⁺CD8⁺ sub-population, respectively.
93 NAD(P)H and FAD autofluorescence imaging reveals metabolic differences in quiescent and activated T
94 cells (Fig. 1, S1). The high resolution multiphoton imaging allows visualization of bulk CD3⁺ and isolated
95 CD3⁺CD8⁺ T cells (Fig. 1A). In the autofluorescence images, the nucleus remains dark as NAD(P)H is
96 primarily located in the cytoplasm and mitochondria, and FAD is primarily in the mitochondria. Immunoflu-
97 orescence labeling of CD4, CD8, and CD69 surface proteins verified cell type and activation (Fig. S2). There
98 were significant differences in cell size, optical redox ratio, NAD(P)H τ_m , NAD(P)H α_1 , and FAD α_1 between
99 quiescent and activated T cells ($p < 0.001$, Fig. 1B-F). Significant changes ($p < 0.001$) in FAD τ_m between
100 quiescent and activated T cells were found only for T cells within the bulk CD3⁺ T cell population (Fig. 1E).
101 Additionally, significant changes ($p < 0.001$) in the short and long lifetimes were observed between quiescent
102 and activated CD3⁺ and CD3⁺CD8⁺ T cells (Fig. S1). These differences in autofluorescence endpoints
103 were consistent across the 6 donors (Fig. 1, S1), at 24 and 48 hr of exposure to the activating antibodies
104 (Fig. S3), and between experiments from two different blood draws (183 days apart) from the same donor
105 (Fig. S4). A slight increase in FAD τ_1 was found in both quiescent and activated CD3⁺ T cells, suggesting
106 a slight change in the microenvironment of bound FAD between CD3⁺ T cells of the same donor from two
107 blood draws; however, no other autofluorescence endpoints were significantly different between the two blood
108 draws.

109 Seahorse OCR and ECAR measurements confirm increased metabolic rates of the activated T cells
110 ($p < 0.001$, Fig. 1H-J). In a metabolic inhibitor experiment (Fig. S5), the redox ratio of activated T cells
111 decreased ($p < 0.001$) with a glycolysis inhibitor (2-deoxy-d-glucose), and the redox ratio of quiescent T cells
112 increased ($p < 0.001$) with oxidative phosphorylation inhibitors (antimycin A and rotenone). Additionally,
113 the glutaminolysis inhibitor BPTES significantly decreased ($p < 0.001$) the optical redox ratio, NAD(P)H τ_m ,
114 and FAD τ_m of both quiescent and activated T cells, suggesting a significant contribution of glutaminolysis
115 to the metabolism of quiescent and activated T cells (Fig. S5).




Figure 1: NAD(P)H and FAD autofluorescence imaging reveals metabolic differences between quiescent and activated T cells. Representative optical redox ratio, NAD(P)H τ_m , and FAD τ_m images of quiescent (columns 1, 3) and activated (columns 2, 4) CD3⁺ (rows 1-3) and CD3⁺CD8⁺ (row 4-6) T cells from two different donors. Scale bar is 20 μm . Cell size (B), optical redox ratio (C), NAD(P)H τ_m (D), FAD τ_m (E), NAD(P)H α_1 (F), and FAD α_1 (G) of quiescent and activated CD3⁺ and CD3⁺CD8⁺ T cells. Black circles represent mean of all data (6 donors), triangles (donors A [dark red], B [medium red], and F [light red]) represent data from female donors, squares (donors C [dark blue], D [medium blue], and E [light blue]) represent data from male donors. Each color shade represents data from an individual donor. Data are mean \pm 99% CI. *** $p < 0.001$. $n = 54$ -1058 cells per donor per group. (H-J) Cellular respiration increases in activated T cells. The oxygen consumption rate (OCR; panel H) and extracellular acidification rate (ECAR, panel I) are increased in activated bulk CD3⁺ and isolated CD3⁺CD8⁺ T cells. The ratio of OCR to ECAR (J) is significantly decreased in activated bulk CD3⁺ and isolated CD3⁺CD8⁺ T cells as compared with that of quiescent T cells. *** $p < 0.001$, Student's t-test, $n = 6$ wells/group CD3⁺CD8⁺ isolation, $n = 12$ wells/group CD3⁺ isolation.

2.2 Machine learning models of autofluorescence imaging endpoints allow classification of quiescent and activated T cells with high accuracy.

Uniform Manifold Approximate and Projection (UMAP) [26], a dimension reduction technique similar to tSNE, was used to visualize how cells cluster from autofluorescence measurements. Neighbors were defined through a cosine distance function computed across the autofluorescence endpoints (optical redox ratio, NAD(P)H τ_m , NAD(P)H τ_1 , NAD(P)H τ_2 , NAD(P)H α_1 , FAD τ_m , FAD τ_1 , FAD τ_2 , and FAD α_1) and cell size for each cell. UMAP was chosen over other techniques, notably PCA or tSNE, for its speed, ability to include non-metric distance functions, and performance on preserving the global structure of the data. UMAP representations of the autofluorescence imaging data reveals separation of quiescent and activated T cells (Fig. 2A-B). The gain ratio of autofluorescence endpoints indicates that NAD(P)H α_1 , cell size, and optical redox ratio are the most important features for classification of activation state of CD3⁺ T cells (Fig. 2C), and NAD(P)H α_1 , optical redox ratio, and NAD(P)H τ_m are the most important features for classification of activation state of CD3⁺CD8⁺ T cells (Fig. 2C). The order of feature importance was consistent across multiple feature selection methods including information gain, χ^2 , and random forest (Fig. S6). Correlation analysis revealed that NAD(P)H α_1 , cell size, and the optical redox ratio are not significantly correlated (Fig. S7), suggesting these features are independent and provide complementary information for classification. NAD(P)H α_1 and τ_m are significantly correlated (Fig. S7), as expected, given that τ_m is computed from α_1 . Similar feature weight and order of importance were observed from analysis without NAD(P)H τ_m and FAD τ_m (Fig. S8), indicating that the multivariate models were not significantly affected by the correlations between the mean lifetimes and the lifetime components.

Classification models were developed to predict T cell activation state from NAD(P)H and FAD autofluorescence imaging endpoints (Fig. 2D-F). To protect against over-fitting, models were trained on data from 4 donors with activation state assigned from culture conditions and tested on data with same-cell CD69 expression immunofluorescence validation from 3 donors (completely independent and non-overlapping observations). Receiver operator characteristic (ROC) curves reveal high classification accuracy for predicting activation in bulk CD3⁺ (AUC = 0.975) and isolated CD3⁺CD8⁺ (AUC = 0.996) T cells, when the models use all autofluorescence endpoints (optical redox ratio, cell size, NAD(P)H τ_m , NAD(P)H τ_1 , NAD(P)H τ_2 , NAD(P)H α_1 , FAD τ_m , FAD τ_1 , FAD τ_2 , and FAD α_1). When the NAD(P)H and FAD autofluorescence imaging endpoints of the T cells are normalized within a donor to the mean value of the quiescent CD3⁺ population, the ROC AUC decreases to 0.857 for CD3⁺ T cells (Fig. 2D) and increases slightly to 0.998 for isolated CD3⁺CD8⁺ T cells. While all 10 NAD(P)H and FAD autofluorescence features achieved the highest classification accuracy (AUC = 0.975) for activation of CD3⁺ T cells, a model using only NAD(P)H

148 α_1 achieved a slightly lower accuracy of 0.965 (Fig. 2E). Models that include cell size or cell size and the
 149 optical redox ratio, endpoints that can be obtained from fluorescence intensity images, were less effective
 150 at accurately predicting activation of bulk CD3⁺ T cells with ROC AUCs of 0.708 and 0.901, respectively
 151 (Fig. 2E). Similar results were obtained for the isolated CD3⁺CD8⁺ T cells, with the highest ROC AUC
 152 values achieved for logistic regression classification models using all 10 autofluorescence imaging endpoints
 153 and NAD(P)H α_1 alone, AUC = 0.996 and 0.994, respectively (Fig. 2F). Similar classification accuracy
 154 was achieved with random forest and support vector machine models using all 10 autofluorescence imaging
 155 endpoints (Fig. S9).




Figure 2: **Autofluorescence imaging endpoints allow classification of quiescent and activated T cells.** (A-B) UMAP data reduction technique allows visual representation of the separation between quiescent ("Q") and activated ("Act") bulk CD3⁺ (A) and isolated CD3⁺CD8⁺ (B) T cells. Each color shade corresponds to a different donor, grays correspond to quiescent cells and green or purple to activated CD3⁺ or CD3⁺CD8⁺ T cells, respectively. (C) Feature weights for classification of quiescent versus activated T cells by the gain ratio method. (D) ROC curves for logistic regression models for classification of activation state within bulk CD3⁺ T cells, bulk CD3⁺ T cells normalized within each donor (CD3⁺ Norm), isolated CD3⁺CD8⁺ T cells, and isolated CD3⁺CD8⁺ T cells normalized within each donor (CD3⁺CD8⁺ Norm). (E-F) ROC curves for logistic regression classification models computed using different features for the classification of (E) quiescent or activated bulk CD3⁺ or (F) isolated CD3⁺CD8⁺ T cells. Models were trained on cells that lacked same cell validation data from donors A, B, C, and D but were known to be quiescent or activated by culture conditions (n = 4131 CD3⁺ cells, n = 2655 CD3⁺CD8⁺ cells), and cells from donors B, E, and F with CD69 validation of activation state were used to test the models (n = 696 CD3⁺ cells, n = 595 CD3⁺CD8⁺ cells).

156 **2.3 Autofluorescence imaging reveals T cell heterogeneity within and across** 157 **donors.**

158 T cell heterogeneity was assessed within and across donors (Fig. 3). Heatmap representation (Fig. 3A) of
159 the z-score of autofluorescence imaging endpoint values at the donor level (each row is the mean data of a
160 single donor, cell type, and activation) reveals that the T cells cluster by activation state (i.e. quiescent and
161 activated cluster separately) and isolation (bulk CD3⁺ or isolated CD3⁺CD8⁺). Corresponding coefficient
162 of variation heatmaps highlight the high intra-donor variability of the size of activated T cells and low
163 intra-donor heterogeneity of the autofluorescence endpoints (Fig. S10).

164 A representative z score heatmap where each row is a single cell from one donor reveals distinct clusters
165 of T cells by autofluorescence imaging endpoints within the quiescent and activated CD3⁺CD8⁺ T cell
166 populations (Fig. 3B). Multiple quiescent and activated T cell populations were observed across all six donors
167 and arises from varied distributions of autofluorescence imaging endpoints within the T cell populations (Fig.
168 3C, S11-12). For example, histograms of the NAD(P)H τ_m values of quiescent and activated CD3⁺CD8⁺ T
169 cells reveals a bimodal population within the quiescent CD3⁺CD8⁺ T cells, with one peak of the quiescent
170 cells consistent with the peak of the activated cells (Fig. 3C).

171 We hypothesized that memory and naïve T cells within the quiescent population contributed to the ob-
172 served heterogeneity within the quiescent CD3⁺CD8⁺ T cell population (Fig. 3B-C, S11-13) (i.e. the multiple
173 clusters of quiescent CD3⁺CD8⁺ cells within the heatmaps and bimodal distribution of the NAD(P)H τ_m
174 of quiescent CD3⁺CD8⁺ T cells). To test this, we co-stained quiescent CD3⁺CD8⁺ T cells with antibodies
175 against CD45RA, a marker of naïve T cells, and CD45RO, a marker of memory T cells. NAD(P)H τ_m was
176 significantly decreased in CD45RO⁺ cells as compared with NAD(P)H τ_m of CD45RA⁺ cells (Fig. 3D).
177 Additionally, the optical redox ratio and NAD(P)H α_1 were increased ($p < 0.01$) in CD45RO⁺ CD3⁺CD8⁺
178 T cells as compared to CD45RA⁺ cells (Fig. S14).

179 **2.4 Culture with CD3⁺CD4⁺ T cells affects the autofluorescence of CD3⁺CD8⁺** 180 **T cells**

181 NAD(P)H and FAD autofluorescence imaging endpoints reveal metabolic differences between CD3⁺CD8⁺ T
182 cells cultured as an isolated population and CD3⁺CD8⁺ T cells cultured with CD3⁺CD4⁺ T cells (bulk CD3⁺
183 isolation). A UMAP (data dimension reduction) representation of NAD(P)H and FAD autofluorescence
184 imaging endpoints reveals that CD3⁺CD8⁺ T cells cultured from the CD3⁺CD8⁺ specific T cell isolations
185 cluster separately from CD3⁺CD8⁺ T cells within bulk CD3⁺ T cell populations (Fig. 4A). The optical redox
186 ratio and NAD(P)H α_1 are decreased in both quiescent and activated CD3⁺CD8⁺ T cells of the isolated




Figure 3: Autofluorescence imaging reveals inter- and intra-donor T cell heterogeneity. (A) Heatmap of z-scores of NAD(P)H and FAD autofluorescence imaging endpoints where each row is the mean data representing a single donor, subtype (CD3⁺ or CD3⁺CD8⁺), and activation. Data clusters by activation state and isolation (bulk CD3⁺ or isolated CD3⁺CD8⁺). (B) Heatmap of z-scores of NAD(P)H and FAD autofluorescence imaging endpoints of CD3⁺CD8⁺ T cells from a single donor, each row is a single cell (n=635 cells). Distinct clusters are identified within the quiescent and activated CD3⁺CD8⁺ T cells. (C) Histogram analysis of NAD(P)H τ_m reveals two populations in quiescent CD3⁺CD8⁺ T cells across all donors (n=2126 quiescent cells, 1352 activated cells). (D) NAD(P)H τ_m is decreased in CD45RO⁺ CD3⁺CD8⁺ T cells compared to NAD(P)H τ_m of CD45RA⁺ CD3⁺CD8⁺ T cells (CD45RA⁺ n=27 cells, CD45RO⁺ n=11 cells from 1 donor, ** p<0.01, - Act = quiescent cells, + Act = cells exposed to anti-CD3/CD2/CD28 for 48hr.)

187 CD3⁺CD8⁺ population as compared to the corresponding values of quiescent and activated CD3⁺CD8⁺ T
188 cells, respectively, within the bulk CD3⁺ population (Fig. 4B-C). Additional differences in NAD(P)H and
189 FAD autofluorescence lifetime endpoints were observed between CD3⁺CD8⁺ T cells within the bulk CD3⁺
190 population and the isolated CD3⁺CD8⁺ population (Fig. S15).

191 Despite these differences between CD3⁺CD8⁺ T cells of CD3⁺CD8⁺ specific isolations and bulk CD3⁺
192 isolations, significant changes in NAD(P)H and FAD autofluorescence endpoints due to activation are main-
193 tained, and classification models predict activation status of CD3⁺CD8⁺ cells with high accuracy regardless
194 of isolation (Fig. 4D). Random forest feature selection revealed that NAD(P)H α_1 is the most important
195 feature for classification of quiescent from activated CD3⁺ or CD3⁺CD8⁺ T cells (Fig. S16A).

196 **2.5 Machine learning models of autofluorescence endpoints classify CD3⁺CD4⁺** 197 **from CD3⁺CD8⁺ T cells within bulk CD3⁺ populations**

198 Heterogeneity in NAD(P)H and FAD autofluorescence endpoints between CD3⁺CD4⁺ and CD3⁺CD8⁺ T
199 cells was observed within the T cells from the bulk CD3⁺ isolation. A UMAP representation of the NAD(P)H
200 and FAD autofluorescence data allows visualization of the clustering and separation of quiescent and activated
201 CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells within the bulk CD3⁺ isolation (Fig. 4E). These differences between
202 CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells are due to significant differences in NAD(P)H and FAD endpoints,
203 including NAD(P)H τ_2 , which is increased ($p < 0.05$) in quiescent CD3⁺CD8⁺ T cells compared to quiescent
204 CD3⁺CD4⁺ T cells, and NAD(P)H α_1 , which is decreased in activated CD3⁺CD8⁺ T cells compared to
205 activated CD3⁺CD4⁺ T cells ($p < 0.05$, Fig. 4F-G, S17). Random forest models to classify T cell subtype
206 (CD3⁺CD4⁺ or CD3⁺CD8⁺) within the bulk CD3⁺ T cell isolation have average predictions of 97.5% and
207 99.7% for separate predictions on subsets of quiescent or activated T cells, respectively, and 99.4% for all
208 four groups, when trained on 75% of the T cell observations and tested on the remaining 25% (Fig. 4H).
209 Classification accuracy scales with number of cells in train versus test groups (Fig. 4H). Random forest
210 feature analysis revealed that NAD(P)H τ_2 is the highest weighted feature for the classification of activated
211 CD3⁺CD4⁺ from activated CD3⁺CD8⁺ T cells, and FAD τ_1 is the highest weighted feature for quiescent
212 CD3⁺CD4⁺ from quiescent CD3⁺CD8⁺ T cells (Fig. S16B).

213 **2.6 Autofluorescence imaging allows classification of activated T cells in cul-** 214 **tures of combined quiescent and activated T cells**

215 NAD(P)H and FAD autofluorescence imaging allows label-free imaging and classification of T cell activation
216 in T cell cultures with combined quiescent and activated cells. A representative NAD(P)H α_1 image with




Figure 4: T cell population composition affects T cell autofluorescence. (A) UMAP of NAD(P)H and FAD autofluorescence endpoints of quiescent and activated (“Act”) CD3⁺CD8⁺ T cells identified within bulk CD3⁺ and specific CD3⁺CD8⁺ isolations. (B) Optical redox ratio and (C) NAD(P)H α_1 of CD3⁺CD8⁺ T cells cultured as an isolated population (CD3⁺CD8⁺ specific isolation, n=39 quiescent cells, n=174 activated cells) and with CD3⁺CD4⁺ T cells (bulk CD3⁺ isolation, n=83 quiescent cells, n=170 activated cells). Stars between quiescent and activated boxplots compare quiescent and activated CD3⁺CD8⁺ T cells within an isolation (CD3⁺ or CD3⁺CD8⁺), stars above the quiescent box plot represent significance between quiescent CD3⁺CD8⁺ T cells from the bulk CD3⁺ and CD3⁺CD8⁺ specific isolations, stars above the activated box plot represent significance between activated CD3⁺CD8⁺ T cells from the bulk CD3⁺ and CD3⁺CD8⁺ specific isolations, ** p<0.01, *** p<0.001. (D) Accuracy of random forest classification of quiescent versus activated CD3⁺CD8⁺ T cells from CD3⁺CD8⁺ specific isolations (n=213 cells) and bulk CD3⁺ isolations (n=253 cells). (E) UMAP of NAD(P)H and FAD autofluorescence imaging endpoints of quiescent and activated CD3⁺CD4⁺ and CD3⁺CD8⁺ cells identified within bulk CD3⁺ populations. (F) NAD(P)H τ_2 of quiescent CD3⁺CD4⁺ and CD3⁺CD8⁺ cells (bulk CD3⁺ isolation, n=66 quiescent CD3⁺CD4⁺ T cells, n=83 quiescent CD3⁺CD8⁺ T cells, * p<0.05, *** p<0.001). (G) NAD(P)H α_1 of activated CD3⁺CD4⁺ and CD3⁺CD8⁺ cells (bulk CD3⁺ isolation, n=264 activated CD3⁺CD4⁺ T cells, n=170 activated CD3⁺CD8⁺ T cells). (H) Accuracy of random forest classification of CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells from quiescent (2 group classification, “CD3⁺ Q”), activated (2 group classification, “CD3⁺ Act”), or both quiescent and activated T cells (4 group classification, “CD3⁺ All”) within bulk CD3⁺ isolations, total observations include 66 quiescent CD3⁺CD4⁺ T cells, 83 quiescent CD3⁺CD8⁺ T cells, 264 activated CD3⁺CD4⁺ T cells, and 170 activated CD3⁺CD8⁺ T cells.

217 CD69 immunofluorescence overlaid in pink, demonstrates the difference in NAD(P)H α_1 between quiescent
218 (CD69⁻) and activated (CD69⁺) T cells (Fig. 5A). UMAP visualization of the autofluorescence imaging
219 data reveals separation of quiescent and activated CD3⁺ T cells within this population of combined quiescent
220 and activated cells (Fig. 5B). When cultured in isolated populations, quiescent and activated T cells have
221 significantly different NAD(P)H and FAD imaging endpoints, including the optical redox ratio and NAD(P)H
222 α_1 , than their respective counterpart from a combined (quiescent with activated T cells) population (Fig.
223 5C-D, Fig. S18). Random forest feature selection for classification of activation status of T cells within a
224 combined, quiescent and activated, T cell population reveals that NAD(P)H α_1 is the most important feature
225 for classification, followed by NAD(P)H τ_m (Fig. S19). Logistic regression models to predict activation status
226 of T cells in a combined, quiescent and activated, CD3⁺ T cell culture achieves ROC AUCs of 0.95 when all
227 10 NAD(P)H and FAD imaging endpoints are included, 0.95 and 0.68 when only predicting from NAD(P)H
228 α_1 or cell size, respectively, and 0.67 for redox ratio and cell size (Fig. 5E).

229 **2.7 Autofluorescence imaging resolves temporal changes in T cells with activa-** 230 **tion**

231 Metabolic changes occur rapidly within T cells upon activation [27]; therefore, we hypothesized that time-
232 course imaging of T cells would resolve changes in T cell autofluorescence. NAD(P)H fluorescence lifetime
233 images were acquired from CD3⁺ quiescent T cells immediately after exposure to the activating tetrameric
234 antibody (anti-CD2/CD3/CD28). The NAD(P)H intensity of the nucleus increased by 10% relative to the
235 pre-activator values, within a few minutes of addition of the activator, and remained consistently higher than
236 the average pre-activation NAD(P)H intensity throughout the time-course (Fig. 5F). NAD(P)H intensity
237 within the nucleus may indicate increased transcription [28]. The NAD(P)H intensity in the cytoplasm
238 initially increased ($t < 1$ m) and then decreased, relative to the pre-activation NAD(P)H intensity of the
239 cytoplasm. NAD(P)H α_1 increased significantly in the cytoplasm by 2% at $t = 6$ minutes post addition of
240 the activator and remained significantly increased until $t = 8.75$ m. These autofluorescence changes observed
241 early, within minutes of activation, indicate that autofluorescence lifetime imaging is sensitive to robust
242 transcription and metabolic changes that occur with activation in T cells [27].

243 **3 Discussion**

244 T cells are an important component of the adaptive immune response with direct cytotoxic and immune-
245 modulating behaviors. Novel immunotherapies that directly modify T cell behavior show promise for treating




Figure 5: Autofluorescence imaging allows classification of quiescent and activated T cells within combined quiescent and activated T cell populations. (A) Representative NAD(P)H α_1 image of combined quiescent (CD69⁻) and activated (CD69⁺) T cells with CD69 immunofluorescence overlaid in pink. Scale bar is 30 μ m. (B) UMAP representation of NAD(P)H and FAD imaging endpoints of CD69⁻ and CD69⁺ CD3⁺ T cells from a combined population of quiescent and activated T cells. (C) Optical redox ratio and (D) NAD(P)H α_1 of isolated ("Iso.") and combined quiescent (CD69⁻) and activated (CD69⁺) CD3⁺ T cells. *** $p < 0.001$, $n=289-438$ cells per group, single donor. (E) ROC curves of logistic regression classification of quiescent and activated CD3⁺ T cells from a combined population of CD69⁻ and CD69⁺ T cells. (F) Percent difference of NAD(P)H α_1 and fluorescence intensity in CD3⁺ T cell nuclei and cytoplasm over time. Anti-CD2/CD3/CD28 added at $t=0$ m. mean +/- SD of 34 cells.

246 a variety of conditions including cancer and autoimmune disease. Due to their varied activities, character-
247 ization of T cell function is imperative for assessment of immunotherapy efficacy for pre-clinical evaluation
248 and quality control of clinical immunotherapies. In this study, we develop autofluorescence lifetime imaging-
249 based methods for determination of T cell activation at the single cell level. Autofluorescence lifetime
250 imaging is non-destructive, label-free, and has high spatial and temporal resolution that is amenable with
251 live cell assessment, longitudinal studies, and *in vivo* imaging. Autofluorescence imaging offers advantages
252 over antibody-labeling methods that are traditionally used to assess T cell function with high specificity
253 which are less amenable to non-invasive time-course studies within intact samples.

254 Upon activation, T cell metabolism switches from tricarboxylic acid oxidation of glucose and β -oxidation
255 of fatty acids to glycolysis and glutaminolysis [23–25, 29, 30]. T cells with high glycolytic activity *in vitro* show
256 poor persistence, low recall responses and low proliferation rates that lead to poor effector activity *in vivo*,
257 whereas T cells with high fatty acid oxidation show increased persistence, recall responses and proliferation
258 leading to better effector activity within the tumor [31]. Changes in NAD(P)H and FAD autofluorescence
259 imaging endpoints, including the increased optical redox ratio observed in activated T cells relative to the
260 optical redox ratio of quiescent T cells, reflect a shift towards glycolysis in activated T cells (Fig. 1, S1,
261 S18-19). Significant changes in the lifetimes of protein-bound NAD(P)H (τ_2) and protein-bound FAD (τ_1 ;
262 Fig. S1) indicate differences in the protein binding partners of NAD(P)H and FAD [32]. A significant
263 increase in the fraction of free NAD(P)H (α_1 ; Fig. 1F) in activated T cells as compared to that of quiescent
264 T cells, suggests a relative increase in free NAD(P)H and a decrease in protein-bound NADH, consistent
265 with a shift from TCA metabolism to glycolysis [33], which was verified by the Seahorse assay and metabolic
266 inhibitor experiment (Fig. 1H-J, S5). The significant increase in the lifetime of free NAD(P)H (τ_1 , Fig. S1),
267 suggests a change in the microenvironment (e.g., pH, oxygen) of the free fraction of NAD(P)H that reduces
268 the quenching of the fluorophore. Altogether, the significant changes observed between NAD(P)H and FAD
269 fluorescence lifetime values reflect changes in the microenvironment of the metabolic coenzymes NAD(P)H
270 and FAD and altered metabolic pathway utilization by quiescent and activated T cells [23–25, 29, 30].

271 T cells are known to be highly heterogeneous, with phenotypic heterogeneity of surface proteins and
272 effector function observed for CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells [34]. This heterogeneity can arise from
273 the strength of the activating event, the microenvironment of the T cell, and differences in gene regulation at
274 the time of activation [35–37]. Heterogeneity analysis, by heatmaps and histograms, revealed heterogeneous
275 clustering of T cells within the autofluorescence imaging dataset. One of these populations within the
276 quiescent CD3⁺CD8⁺ population, was identified due to a difference in the mean NAD(P)H lifetime which
277 was found to be due to naïve (CD45RO⁺) and memory (CD45RA⁺) CD3⁺CD8⁺ T cells (Fig. 3C-D),
278 which are known to have differing metabolic states: memory T cells have increased glycolytic capacity and

279 mitochondrial mass as compared with naïve T cells [27]. An additional subpopulation was identified within
280 the activated T cell subset and characterized by larger than average cells (Fig. 3B, S6-7). These large cells
281 may be actively dividing cells, a condition which is also accompanied by metabolic and autofluorescence
282 differences [38, 39].

283 Machine learning approaches are powerful tools for classification of biomedical imaging data and have
284 been used on extracted morphological features of phase-contrast images to identify cancer cells from immune
285 cells, on brightfield images to assess cell cycle, and on phase contrast and autofluorescence images to classify
286 macrophage exposure to LPS [22, 40, 41]. Here, high ROC AUCs (0.95+) were achieved using machine
287 learning techniques to classify T cells as activated or quiescent using the autofluorescence imaging endpoints
288 (optical redox ratio, cell size, NAD(P)H τ_m , NAD(P)H τ_1 , NAD(P)H τ_2 , NAD(P)H α_1 , FAD τ_m , FAD
289 τ_1 , FAD τ_2 , and FAD α_1) quantified for each cell. Classification of activation of T cells from CD3⁺CD8⁺
290 specific isoations was slightly higher than that of T cells from bulk CD3⁺ isolations as might be expected for
291 a homogeneous population (CD3⁺CD8⁺) rather than a heterogeneous population (bulk CD3⁺ populations
292 contain CD4⁺ and CD8⁺ subsets). Although multiple classification models were found to have similar
293 performance, logistic regression was the best fitting model, suggesting that the predicted probability of
294 activation is a linear combination of all 10 of the autofluorescence imaging endpoints. Interestingly, donor
295 normalization (Fig. 2D) of the autofluorescence imaging endpoints did not improve classification accuracy,
296 suggesting that the autofluorescence endpoints reflect changes in T cells with activation that are consistent
297 across donors so generalized models can be used for unspecified donors or patients, which is beneficial for
298 robust implementation of autofluorescence imaging as a universal tool to evaluate T cell activation.

299 The models for classification of activation in T cells reported here have higher ROC AUC values than the
300 previously reported accuracy of 84-87% found for binary logistic regression classification of morphological
301 and Raman spectra features of control and LPS-exposed macrophages [22]. The increased accuracy obtained
302 in our study could be due to the metabolic information gained from the NAD(P)H and FAD autofluorescence
303 signals, differences in the heterogeneity of the measured populations, and/or differing numbers of cells in the
304 training and testing data sets. Although high classification accuracy was achieved with the machine learning
305 approaches, deep learning methods such as neural networks may achieve improvements in classification
306 accuracy, as has been demonstrated for the classification of cancer cells from immune cells in phase-contrast
307 images [40].

308 NAD(P)H α_1 was consistently identified as the most important feature for differentiation of quiescent
309 and activated T cells across different feature selection methods (including gain ratio, information gain, χ^2 ,
310 and random forest), and different subsets of CD3⁺, CD3⁺CD8⁺, and CD69⁺/CD69⁻ T cells (Fig. 2C, S6,
311 S19). The classification analysis also revealed that while models trained on all 10 autofluorescence imaging

312 endpoints yielded the highest accuracy for classification of activation state of T cells, logistic regression
313 using only NAD(P)H α_1 yielded comparably high ROC AUCs and was more accurate for predicting T cell
314 activation than cell size alone (Fig. 2E), or fluorescence intensity measurements (cell size + redox ratio),
315 which can be obtained by wide-field or confocal fluorescence microscopy. Additional label-free methods,
316 including third harmonic generation imaging and Raman spectroscopy of quiescent and activated splenic-
317 derived murine T cells have revealed a significant increase in cell size and lipid content in activated T cells
318 [42]. However, we observed a high variance in cell size within and across patients, which makes it a less
319 important predictor than NAD(P)H lifetime values that change with activation and have lower variance
320 (Fig. S10).

321 CD3⁺CD4⁺ T cells have a variety of immune-modulating behaviors. While not necessary for activation
322 of CD3⁺CD8⁺ T cells, the presence of CD3⁺CD4⁺ T cells during activation is required for the development
323 of memory CD3⁺CD8⁺ T cells [43]. Additionally, T_{REGS} (CD3⁺CD4⁺FoxP3⁺ T cells, 5-10% of peripheral
324 CD3⁺CD4⁺ population) suppress the activation and proliferation of other T cells [44, 45]. Differences in the
325 NAD(P)H and FAD autofluorescence imaging endpoints (Fig. 4, S15) between CD3⁺CD8⁺ T cells cultured
326 with and without CD3⁺CD4⁺ T cells were observed, suggesting autofluorescence imaging is sensitive to
327 CD3⁺CD4⁺ induced changes in CD3⁺CD8⁺ T cells (Fig. 4). However, despite these differences, NAD(P)H
328 α_1 remains the highest weighted feature for classification of activation state (Fig. S16), and activation state of
329 CD3⁺CD8⁺ T cells can be classified from autofluorescence imaging endpoints with high accuracy, regardless
330 of T cell population (Fig. 4D).

331 Due to the differing physiological functions of CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells [1, 46], it is impor-
332 tant to detect CD3⁺CD4⁺ and CD3⁺CD8⁺ subtypes of T cells in addition to the activation state of T
333 cells. Therefore, we explored whether machine learning methods could use autofluorescence imaging data
334 to distinguish between CD3⁺CD8⁺ and CD3⁺CD4⁺ T cells within bulk CD3⁺ populations. Significant
335 differences in NAD(P)H fluorescence lifetime values between CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells suggests
336 variations in metabolic activity upon activation of CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells, which is consis-
337 tent with previously observed differences in CD3⁺CD4⁺ and CD3⁺CD8⁺ T cell activation: CD3⁺CD4⁺
338 activation occurs through Myc, ERR α , and mTOR, while CD3⁺CD8⁺ T cells activate through Akt and
339 mTOR [47]. These subtle differences in metabolic pathway utilization by CD3⁺CD4⁺ and CD3⁺CD8⁺ T
340 cells enabled high classification accuracy of not only quiescent CD3⁺CD4⁺ from quiescent CD3⁺CD8⁺ cells
341 and activated CD3⁺CD4⁺ from activated CD3⁺CD8⁺ cells, but also all four groups, activated and quiescent
342 CD3⁺CD4⁺ from activated and quiescent CD3⁺CD8⁺ accurately (Fig. 4H). Although successful classifi-
343 cation was achieved for CD3⁺CD4⁺ versus CD3⁺CD8⁺ T cells, these changes are much subtler than the
344 metabolic changes with activation, as evidenced by the increased number of cells needed to train the models

345 to achieve high classification accuracy (Fig. 4D,H).

346 Autofluorescence lifetime imaging has spatial and temporal resolution advantages over traditional assays
347 to survey T cell activation and function. Autofluorescence imaging can be high resolution to allow mea-
348 surements at the single cell level, allowing insights into metabolic heterogeneity within T cell populations.
349 Additionally, the high spatial resolution and non-destructive nature of autofluorescence imaging maintains
350 the spatial integrity of immune cells, allowing high fidelity measurements on neighboring cells as demon-
351 strated in the combined population of quiescent and activated T cells (Fig. 5A). Finally, autofluorescence
352 imaging also has high temporal resolution (Fig. 5F) allowing time-course study of T cell activation. Alto-
353 gether, autofluorescence lifetime imaging of NAD(P)H and FAD of T cells, combined with machine learning
354 for classification, is a powerful tool for non-destructive, label-free assessment of activation status of T cells.
355 NAD(P)H and FAD autofluorescence lifetime imaging is label-free and provides high spatial, temporal, and
356 functional information of cell metabolism, which makes it an attractive tool to evaluate T cells *in vivo* or
357 characterize expanded T cells.

358 4 Methods

359 4.1 T cell Isolation and Culture

360 This study was approved by the Institutional Review Board of the University of Wisconsin-Madison (#2018-
361 0103), and informed consent was obtained from all donors. Peripheral blood was drawn from 6 healthy
362 donors into sterile syringes containing heparin. Two blood draws, 183 days apart, were performed on one
363 donor to evaluate the consistency of the experimental protocol and imaging endpoints. Bulk CD3⁺ T cells
364 or an isolated CD3⁺CD8⁺ T cell subset were extracted from whole blood using negative selection methods
365 (RosetteSep, StemCell Technologies) and cultured in ImmunoCult-XF T cell Expansion Medium (StemCell
366 Technologies). Approximately 24 hours post-isolation, the T cells were divided into two groups, a “quiescent”
367 population that was grown in medium without activating antibodies, and an “activated” population that was
368 cultured in medium supplemented with 25 µl/ml tetrameric antibody against CD2/CD3/CD28 (StemCell
369 Technologies). Quiescent and activated T cell populations were cultured separately for 48 hours at 37°C,
370 5% CO₂, and 99% humidity before imaging and subsequent experiments, unless otherwise noted. Prior to
371 imaging, T cells were plated at approximately 200,000 cells/200 µl media on 35 mm poly-d-lysine coated
372 glass bottom dishes (MatTek). To ensure that autofluorescence imaging and the classification models extend
373 for mixed populations of quiescent and activated T cells, a subset of quiescent and activated T cells (48hr of
374 culture with activating antibody) were combined and plated together in a dish 1 hour before imaging.

375 **4.2 Autofluorescence Imaging of NAD(P)H and FAD**

376 Fluorescence images were acquired using an Ultima (Bruker Fluorescence Microscopy) two-photon microscope
377 coupled to an inverted microscope body (TiE, Nikon) with an Insight DS+ (Spectra Physics) as the excitation
378 source. A 100X objective (Nikon Plan Apo Lambda, NA 1.3), lending an approximate field of view of 110 μm ,
379 was used in all experiments with the laser tuned to 750 nm for NAD(P)H two-photon excitation and 890 nm
380 for FAD two-photon excitation. NAD(P)H and FAD images were acquired sequentially through 440/80 nm
381 and 500/100 nm bandpass filters (Chroma), respectively, by GaAsP photomultiplier tubes (PMTs; H7422,
382 Hamamatsu). The laser power at the sample was 3.0-3.2 mW for NAD(P)H and 4.1-4.3 mW for FAD. Lifetime
383 imaging was performed within Prairie View (Bruker Fluorescence Microscopy) using time-correlated single
384 photon counting electronics (SPC-150, Becker & Hickl, Berlin, Germany). Fluorescence lifetime decays with
385 256 time bins were acquired across 256x256 pixel images with a pixel dwell time of 4.6 μs and an integration
386 time of 60 s. Photon count rates were $\sim 1\text{-}5 \times 10^5$ and monitored during image acquisition to ensure that no
387 photobleaching occurred. The second harmonic generation at 890 nm from red blood cells was used as the
388 instrument response function and had a full width at half maximum of 240 ps. A YG fluorescent bead ($\tau =$
389 2.13 \pm 0.03 ns, $n = 6$) was imaged daily as a fluorescence lifetime standard [14, 18, 48]. Four to six images
390 per group were acquired.

391 **4.3 Antibody Validation**

392 Antibodies against CD4 (clone OKT4, PerCP-conjugated, Biolegend Item #317431, Lot B198303), CD8
393 (clone SK1, PerCP-conjugated, Biolegend Item #344707, Lot B204988), CD69 (clone FN50, PerCP-
394 conjugated, Biolegend Item #310927, Lot B180058), CD45RA (clone HI100, Alexa 647-conjugated, Bi-
395 olegend Item #304153, Lot B220325), and CD45RO (clone UCHL1, PerCP-conjugated, Biolegend Item
396 #304251, Lot B219295) were used for validation of cell type and activation. Cells (30,000-200,000 per
397 condition) were stained with 5 μl antibody/ 10^6 cells in 50 μl of ImmunoCult-XF T cell Expansion Medium
398 for 30 minutes in the dark at room temperature. Cells were washed with ImmunoCult 1-2 times, resuspended
399 in 50-200 μl of media, and added to the center of a 35 mm poly-d-lysine coated glass bottom dish (MatTek).
400 Cells were kept in a 37°C, 5% CO₂, humidified environment until imaging. All cells were imaged within 3
401 hours of staining. NAD(P)H and FAD fluorescence lifetime images were acquired as described. To identify
402 PerCP positive cells, an additional fluorescence intensity image was acquired with the Titanium:Sapphire
403 laser tuned to 1040 nm and a 690/45 nm bandpass filter before the PMT. For evaluation of Alexa647
404 fluorescence, the Titanium:Sapphire laser was tuned to 1300 nm for excitation, and a 690/45 nm bandpass
405 filter was used to filter emitted light.

4.4 Data Analysis

Fluorescence lifetime decays were analyzed to extract fluorescence lifetime components (SPCImage, Becker & Hickl). A bin of 9 surrounding pixels (3x3) was used to increase the fluorescence counts in each decay. A threshold was used to exclude pixels with low fluorescence signal (i.e. background). Fluorescence lifetime decays were deconvolved from the instrument response function and fit to a 2 component exponential decay model, $I(t) = \alpha_1 e^{-t/\tau_1} + \alpha_2 e^{-t/\tau_2} + C$, where $I(t)$ is the fluorescence intensity as a function of time, t , after the laser pulse, α_1 and α_2 are the fractional contributions of the short and long lifetime components, respectively (i.e., $\alpha_1 + \alpha_2 = 1$), τ_1 and τ_2 are the short and long lifetime components, respectively, and C accounts for background light. Both NAD(P)H and FAD can exist in quenched (short lifetime) and unquenched (long lifetime) configurations [9, 13]; therefore, the fluorescence decays of NAD(P)H and FAD are fit to two components.

Images were analyzed at the single cell level to evaluate cellular heterogeneity [49]. NAD(P)H intensity images were segmented into cytoplasm and nucleus using edge detect and thresholding methods in CellProfiler using a customized image processing routine [50]. Images of the optical redox ratio (fluorescence intensity of NAD(P)H divided by the summed intensity of NAD(P)H and FAD) and mean fluorescence lifetimes ($\tau_m = \alpha_1 \tau_1 + \alpha_2 \tau_2$) of NAD(P)H and FAD were computed (MATLAB). NAD(P)H and FAD autofluorescence imaging endpoints, including the optical redox ratio, NAD(P)H τ_m , NAD(P)H τ_1 , NAD(P)H τ_2 , NAD(P)H α_1 , FAD τ_m , FAD τ_1 , FAD τ_2 , and FAD α_1 were averaged across all pixels within a cell cytoplasm for each segmented cell. Cell size in μm^2 was also computed from the segmented images using the number of pixels within the 2D-image of the cell * 0.167 μm^2 (which is the pixel dimension).

Statistical analysis and data representation were performed in R. A generalized linear model was used to evaluate significant differences ($\alpha = 0.05$) of autofluorescence imaging endpoints between quiescent and activated T cells, CD45RA⁺ and CD45RO⁺ cells (Fig. 3), and CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells. Presented boxplots are constructed from the median (central line) and first and third quartiles (lower and upper hinges, respectively). The whiskers extend to the farthest data points that are no further than 1.5* the interquartile range. Dots represent data points beyond 1.5* the interquartile range from the hinge.

4.5 Classification

Uniform Manifold Approximate and Projection (UMAP), a dimension reduction technique [26], and z-score heatmaps were used to visualize clustering within autofluorescence imaging data sets (Python and R, respectively). Machine learning classification models and training/testing data sets are summarized in Table S1. Random forest, logistic regression, and support vector machine classification methods were trained to

437 classify activated and quiescent T cells within either the bulk CD3⁺ FLIM data or the isolated CD3⁺CD8⁺
438 FLIM data (R). For both data sets, gain ratio, χ^2 , and random forest feature selection methods were em-
439 ployed to evaluate the contribution of the NAD(P)H and FAD autofluorescence endpoints to the accuracy
440 of classification of quiescent versus activated T cells. These models were trained on data from donors A, B,
441 C, and D because these cells lacked immunofluorescence CD69 validation but were known to be quiescent or
442 activated by culture conditions (n = 4131 CD3⁺ cells, n = 2655 CD3⁺CD8⁺ cells). Models were tested on
443 data from T cells from donors B, E, and F with CD69 immunofluorescence validation of activation state (n
444 = 696 CD3⁺ cells, n = 595 CD3⁺CD8⁺ cells). Random forest models were developed to classify CD3⁺CD4⁺
445 from CD3⁺CD8⁺ T cells, and cells were randomly assigned to training and test data sets for a range of
446 train/test proportions from 12.5% to 87.5%. Each model was replicated 50 times with new training and test
447 data generated before each iteration. Logistic regression models were also estimated for the classification of
448 T cell activation from imaging endpoints of combined quiescent and activated CD3⁺ T cells (both condi-
449 tions together within the images). Observations were randomly divided into training and testing data sets
450 (90%/10%, respectively), and presented ROC curves are the average of 1000 iterations of randomly selected
451 training and testing data.

452 **4.6 Seahorse Assay**

453 Quiescent and activated T cells were plated at 5×10^6 cells/ml on a Seahorse 96-well plate in unbuffered
454 RPMI medium without serum. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR)
455 measurements were obtained every 6.5 minutes for 5 cycles. A generalized linear model was used to determine
456 statistical significance ($\alpha = 0.05$) within OCR and ECAR measurements between control and activated T
457 cells.

458 **4.7 Metabolic Inhibitors**

459 Quiescent and activated (48 hr) CD3⁺ T cells were plated on poly-d-lysine coated 35 mm glass bottom
460 dishes at a concentration of $\sim 200,000$ cells/200 μ l ImmunoCult T cell Expansion Medium as previously
461 described (T cell Isolation and Culture). The metabolic inhibitors antimycin A (1 μ M), rotenone (1 μ M),
462 2-deoxy-d-glucose (2DG, 50 mM), Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES, 20
463 μ M), and 5-(Tetradecyloxy)-2-furoic acid (TOFA, 50 1 μ g/ml) were added singly, except for antimycin
464 A and rotenone which were added together, to the dishes prior to imaging. Cells were incubated with
465 antimycin A and rotenone for ten minutes, 2DG for ten minutes, BPTES for 1 hour, and TOFA for 1 hour.
466 Fluorescence lifetime images of NAD(P)H and FAD were acquired for 6 random fields of view as described

467 above. A generalized linear model was used to determine autofluorescence imaging endpoints with statistical
468 significance ($\alpha = 0.05$) between control and inhibitor-exposed cells.

469 **4.8 Activation Time Course**

470 Quiescent CD3⁺ T cells were isolated and plated for imaging as previously described. NAD(P)H lifetime
471 images were acquired as described but with an image size of 128x128 pixels and an integration time of 15
472 s. Images were acquired sequentially for 2 minutes (8 frames), then 5 μ l PBS was added to the cells as
473 a mock treatment, and NAD(P)H fluorescence lifetime images were acquired for 10 minutes (40 frames).
474 Subsequently, 5 μ l of activating tetrameric antibody (anti-CD2/CD3/CD28) was added and NAD(P)H flu-
475 orescence lifetime images were acquired for 10 minutes (40 frames). NAD(P)H FLIM images were analyzed
476 in SPCImage as described. Individual cells and cell compartments (nucleus, cytoplasm) were manually seg-
477 mented (author I.J.), and the autofluorescence imaging endpoints were averaged across all pixels within the
478 segmented region (ImageJ). This procedure was repeated for 3 dishes for a total of 34 analyzed cells.

479 **4.9 Data Availability**

480 The datasets generated during and/or analyzed during the current study are available from the corresponding
481 authors on reasonable request.

482 **4.10 Code Availability**

483 All code and algorithms generated during the current study are available from the corresponding authors on
484 reasonable request.

485 **References**

- 486 1. Mosmann, T. R. & Coffman, R. L. in *Advances in Immunology Volume 46* 111–147 (Elsevier, 1989).
- 487 2. Bettelli, E., Korn, T. & Kuchroo, V. K. Th17: the third member of the effector T cell trilogy. *Current*
488 *Opinion in Immunology* **19**, 652–657 (Dec. 2007).
- 489 3. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. *Nature Reviews Cancer*
490 **12**, 252–264 (Apr. 2012).
- 491 4. Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the
492 T cell response. *Nature Reviews Immunology* **12**, 269–281 (Apr. 2012).

- 493 5. Canavan, J. B. *et al.* Developing in vitro expanded CD45RA+regulatory T cells as an adoptive cell
494 therapy for Crohn's disease. *Gut* **65**, 584–594 (Feb. 2015).
- 495 6. Marek-Trzonkowska, N. *et al.* Administration of CD4+CD25highCD127- Regulatory T Cells Preserves
496 -Cell Function in Type 1 Diabetes in Children. *Diabetes Care* **35**, 1817–1820 (June 2012).
- 497 7. Todo, S. *et al.* A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in
498 living donor liver transplantation. *Hepatology* **64**, 632–643 (Mar. 2016).
- 499 8. Chance, B., Schoener, B., Oshino, R., Itshak, F. & Nakase, Y. Oxidation-reduction ratio studies of mi-
500 tochondria in freeze-trapped samples. NADH and flavoprotein fluorescence signals. *Journal of Biological*
501 *Chemistry* **254**, 4764–4771 (1979).
- 502 9. Lakowicz, J. R., Szmajcinski, H., Nowaczyk, K. & Johnson, M. L. Fluorescence lifetime imaging of free
503 and protein-bound NADH. *Proceedings of the National Academy of Sciences* **89**, 1271–1275 (Feb. 1992).
- 504 10. Georgakoudi, I. & Quinn, K. P. Optical imaging using endogenous contrast to assess metabolic state.
505 *Annual review of biomedical engineering* **14**, 351–367 (2012).
- 506 11. Huang, S., Heikal, A. A. & Webb, W. W. Two-Photon Fluorescence Spectroscopy and Microscopy of
507 NAD(P)H and Flavoprotein. *Biophysical Journal* **82**, 2811–2825 (May 2002).
- 508 12. Varone, A. *et al.* Endogenous Two-Photon Fluorescence Imaging Elucidates Metabolic Changes Re-
509 lated to Enhanced Glycolysis and Glutamine Consumption in Precancerous Epithelial Tissues. *Cancer*
510 *Research* **74**, 3067–3075 (Mar. 2014).
- 511 13. Nakashima, N., Yoshihara, K., Tanaka, F. & Yagi, K. Picosecond fluorescence lifetime of the coenzyme
512 of D-amino acid oxidase. *Journal of Biological Chemistry* **255**, 5261–5263 (1980).
- 513 14. Skala, M. C. *et al.* In vivo multiphoton microscopy of NADH and FAD redox states, fluorescence
514 lifetimes, and cellular morphology in precancerous epithelia. *Proceedings of the National Academy of*
515 *Sciences* **104**, 19494–19499 (Nov. 2007).
- 516 15. Quinn, K. P. *et al.* Quantitative metabolic imaging using endogenous fluorescence to detect stem cell
517 differentiation. *Scientific Reports* **3** (Dec. 2013).
- 518 16. Walsh, A. J. *et al.* Quantitative Optical Imaging of Primary Tumor Organoid Metabolism Predicts
519 Drug Response in Breast Cancer. *Cancer Research* **74**, 5184–5194 (Aug. 2014).
- 520 17. Walsh, A. J., Castellanos, J. A., Nagathihalli, N. S., Merchant, N. B. & Skala, M. C. Optical Imaging
521 of Drug-Induced Metabolism Changes in Murine and Human Pancreatic Cancer Organoids Reveals
522 Heterogeneous Drug Response. *Pancreas* **45**, 863–869 (July 2016).

- 523 18. Walsh, A. J. *et al.* Optical Metabolic Imaging Identifies Glycolytic Levels, Subtypes, and Early Treat-
524 ment Response in Breast Cancer. *Cancer Research* **73**, 6164–6174 (Oct. 2013).
- 525 19. Stringari, C. *et al.* Phasor approach to fluorescence lifetime microscopy distinguishes different metabolic
526 states of germ cells in a live tissue. *Proceedings of the National Academy of Sciences* **108**, 13582–13587
527 (Aug. 2011).
- 528 20. Alfonso-García, A. *et al.* Label-free identification of macrophage phenotype by fluorescence lifetime
529 imaging microscopy. *Journal of Biomedical Optics* **21**, 046005 (Apr. 2016).
- 530 21. Szulczewski, J. M. *et al.* In Vivo Visualization of Stromal Macrophages via label-free FLIM-based
531 metabolite imaging. *Scientific Reports* **6** (May 2016).
- 532 22. Pavillon, N., Hobro, A. J., Akira, S. & Smith, N. I. Noninvasive detection of macrophage activation
533 with single-cell resolution through machine learning. *Proceedings of the National Academy of Sciences*
534 **115**, E2676–E2685 (Mar. 2018).
- 535 23. Frauwirth, K. A. *et al.* The CD28 Signaling Pathway Regulates Glucose Metabolism. *Immunity* **16**,
536 769–777 (June 2002).
- 537 24. Chang, C.-H. *et al.* Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis. *Cell*
538 **153**, 1239–1251 (June 2013).
- 539 25. Michalek, R. D. *et al.* Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are
540 Essential for Effector and Regulatory CD4+ T Cell Subsets. *The Journal of Immunology* **186**, 3299–
541 3303 (Feb. 2011).
- 542 26. McInnes, L. & Healy, J. UMAP: Uniform Manifold Approximation and Projection for Dimension Re-
543 duction. arXiv: <http://arxiv.org/abs/1802.03426v1> (Feb. 9, 2018).
- 544 27. Van der Windt, G. J. W. *et al.* CD8 memory T cells have a bioenergetic advantage that underlies their
545 rapid recall ability. *Proceedings of the National Academy of Sciences* **110**, 14336–14341 (Aug. 2013).
- 546 28. Zhang, Q., Piston, D. W. & Goodman, R. H. Regulation of Corepressor Function by Nuclear NADH.
547 *Science* **295**, 1895–1897. ISSN: 0036-8075 (2002).
- 548 29. Wang, R. *et al.* The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte
549 Activation. *Immunity* **35**, 871–882 (Dec. 2011).
- 550 30. Wang, R. & Green, D. R. Metabolic checkpoints in activated T cells. *Nature Immunology* **13**, 907–915
551 (Sept. 2012).
- 552 31. Kishton, R. J., Sukumar, M. & Restifo, N. P. Metabolic Regulation of T Cell Longevity and Function
553 in Tumor Immunotherapy. *Cell Metabolism* **26**, 94–109 (July 2017).

- 554 32. Sharick, J. T. *et al.* Protein-bound NAD(P)H Lifetime is Sensitive to Multiple Fates of Glucose Carbon.
555 *Scientific Reports* **8** (Apr. 2018).
- 556 33. Liu, Z. *et al.* Mapping metabolic changes by noninvasive, multiparametric, high-resolution imaging
557 using endogenous contrast. *Science Advances* **4**. doi:10.1126/sciadv.aap9302 (Mar. 2018).
- 558 34. Chang, J. T., Wherry, E. J. & Goldrath, A. W. Molecular regulation of effector and memory T cell
559 differentiation. *Nature Immunology* **15**, 1104–1115 (Dec. 2014).
- 560 35. Kaech, S. M. & Cui, W. Transcriptional control of effector and memory CD8+ T cell differentiation.
561 *Nature Reviews Immunology* **12**, 749–761 (Oct. 2012).
- 562 36. Palmer, M. J., Mahajan, V. S., Chen, J., Irvine, D. J. & Lauffenburger, D. A. Signaling thresholds
563 govern heterogeneity in IL-7-receptor-mediated responses of naïve CD8+ T cells. *Immunology and Cell*
564 *Biology* **89**, 581–594 (Feb. 2011).
- 565 37. Tubo, N. J. *et al.* Single Naive CD4+ T Cells from a Diverse Repertoire Produce Different Effector Cell
566 Types during Infection. *Cell* **153**, 785–796 (May 2013).
- 567 38. Krylov, S. N. *et al.* Correlating cell cycle with metabolism in single cells: Combination of image and
568 metabolic cytometry. *Cytometry* **37**, 14–20 (Sept. 1999).
- 569 39. Heaster, T. M., Walsh, A. J., Zhao, Y., Hiebert, S. W. & Skala, M. C. Autofluorescence imaging identifies
570 tumor cell-cycle status on a single-cell level. *Journal of Biophotonics* **11**, e201600276 (May 2017).
- 571 40. Chen, C. L. *et al.* Deep Learning in Label-free Cell Classification. *Scientific Reports* **6** (Mar. 2016).
- 572 41. Blasi, T. *et al.* Label-free cell cycle analysis for high-throughput imaging flow cytometry. *Nature Com-*
573 *munications* **7**, 10256 (Jan. 2016).
- 574 42. Gavgiotaki, E. *et al.* Detection of the T cell activation state using non-linear optical microscopy. *Journal*
575 *of Biophotonics*, e201800277 (Oct. 2018).
- 576 43. Janssen, E. M. *et al.* CD4+ T cells are required for secondary expansion and memory in CD8+ T
577 lymphocytes. *Nature* **421**, 852–856 (Feb. 2003).
- 578 44. Takahashi, T. *et al.* Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Con-
579 stitutively Expressing Cytotoxic T Lymphocyte-Associated Antigen 4. *The Journal of Experimental*
580 *Medicine* **192**, 303–310 (July 2000).
- 581 45. Dieckmann, D., Plottner, H., Berchtold, S., Berger, T. & Schuler, G. Ex Vivo Isolation and Char-
582 acterization of Cd4+Cd25+T Cells with Regulatory Properties from Human Blood. *The Journal of*
583 *Experimental Medicine* **193**, 1303–1310 (June 2001).

- 584 46. Naito, Y. *et al.* CD8+ T Cells Infiltrated within Cancer Cell Nests as a Prognostic Factor in Human
585 Colorectal Cancer. *Cancer Research* **58**, 3491–3494 (1998).
- 586 47. Gerriets, V. A. & Rathmell, J. C. Metabolic pathways in T cell fate and function. *Trends in Immunology*
587 **33**, 168–173 (Apr. 2012).
- 588 48. Bird, D. K. *et al.* Metabolic Mapping of MCF10A Human Breast Cells via Multiphoton Fluorescence
589 Lifetime Imaging of the Coenzyme NADH. *Cancer Research* **65**, 8766–8773 (Oct. 2005).
- 590 49. Walsh, A. J. & Skala, M. C. Optical metabolic imaging quantifies heterogeneous cell populations.
591 *Biomedical Optics Express* **6**, 559 (Jan. 2015).
- 592 50. Walsh, A. J. & Skala, M. C. *An automated image processing routine for segmentation of cell cytoplasm*
593 *in high-resolution autofluorescence images in Multiphoton Microscopy in the Biomedical Sciences XIV*
594 (SPIE, Feb. 2014).

595 **5 Acknowledgments**

596 The authors would like to thank Arezoo Movaghar for insightful discussions of feature selection and machine
597 learning classification methods and Rebecca Schmitz for her assistance with formatting of paper figures. This
598 work was funded by the NIH NCI R01 CA205101 (to M.C.S); the Biotechnology Training Program of the
599 National Institute of General Medical Sciences of the National Institutes of Health, award #T32GM008349
600 (to K.S.); NIH awards R01DK098672 and P41GM108538 (to D.J.P.) and T32DK007665 (to N.M.N.); the
601 NSF Graduate Research Fellowship Program, DGE-1747503 (to K.M); and the National Science Foundation
602 under Grant No. EEC-1648035 (to K.S.).

603 **6 Author Contributions**

604 AW and MS conceived the central hypotheses, and KM contributed the hypothesis on distinguishing
605 CD3⁺CD8⁺ naïve versus memory T cell autofluorescence properties. KM and AW designed and performed
606 the experiments with assistance from NP. AW and IJ analyzed the data. NN and KM performed the
607 Seahorse assay. CW provided statistical insight and data analysis code. KS and MS supervised the project.
608 AW wrote the initial draft of the manuscript. All authors contributed to data interpretation and the final
609 manuscript.

610 **7 Competing Interests**

611 A patent application has been filed on this work.

612 **8 Correspondence**

613 Correspondence to Alex J. Walsh or Melissa C. Skala.